The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INAB | -79.26% | N/A | N/A | -99% |
| S&P | +13% | +86.41% | +13.26% | +54% |
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.40M | 41.9% |
| Market Cap | $9.85M | -22.0% |
| Market Cap / Employee | $0.58M | -17.4% |
| Employees | 17 | -5.6% |
| Net Income | -$3.85M | 45.6% |
| EBITDA | -$3.57M | 33.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.69M | 167.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.88M | -49.9% |
| Short Term Debt | $1.08M | -37.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -126.22% | 24.9% |
| Return On Invested Capital | -92.91% | -330.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.52M | 42.3% |
| Operating Free Cash Flow | -$3.52M | 42.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.29 | 0.97 | 0.41 | 0.58 | -60.52% |
| Price to Tangible Book Value | 42.04 | 24.93 | 0.41 | 0.58 | -97.90% |
| Enterprise Value to EBITDA | -2.27 | -1.19 | 0.32 | -0.59 | -77.73% |
| Return on Equity | -154.4% | -174.7% | -165.6% | -189.7% | -21.59% |
| Total Debt | $5.03M | $4.27M | $3.12M | $2.96M | -45.96% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
